Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas
Status:
Not yet recruiting
Trial end date:
2030-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether combining of Temozolomide and
cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with
Malignant Gliomas. The effectiveness and safety of CIK cells for the treatment of Malignant
Glioma is also evaluated.